ClinicalTrials.gg
CompletedNCT03678870Updated Feb 17, 2020Results posted

Discharge Opioid Education to Decrease Opioid Use After Cesarean

An interventional study of Opioid Education Handout in Opioid Use, sponsored by Vanderbilt University Medical Center. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-17.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. The abundance of prescription opioids available is a primary pathway for opioid abuse and diversion and higher opioid use after surgery has been associated with an increased risk of chronic opioid use. Reducing the amount of opioid used after cesarean delivery may decrease the risk of chronic opioid use and will help towards better estimating and reducing the amount of opioids prescribed at discharge.

Objective: To to compare discharge opioid education to standard care to ascertain whether opioid education reduces opioid use after hospital discharge

Read the detailed description

Background: The number of opioid overdose deaths in the United States has quadrupled in 15 years, a dramatic manifestation of the current opioid abuse epidemic. This rise parallels a sharp increase in the amount of legal prescription opioids dispensed. The abundance of prescription opioids available is a primary pathway for opioid abuse and diversion and higher opioid use after surgery has been associated with an increased risk of chronic opioid use. Reducing the amount of opioid used after cesarean delivery may decrease the risk of chronic opioid use and will help towards better estimating and reducing the amount of opioids prescribed at discharge.

Objective: To to compare discharge opioid education to standard care to ascertain whether opioid education reduces opioid use after hospital discharge

Preliminary Data: Our soon to be published study (Obstetrics \& Gynecology Journal) found that 30% of women used all their opioids after discharge for cesarean delivery because they "were following directions" and not because they had pain.

Enrollment \& Randomization

Enrollment

  • Participants will be approached after their cesarean delivery either in the recovery room or in their private postpartum room
  • Informed written consent will be obtained by a trained research assistant (i.e. medical student) or by the study researchers (Attendings, fellows)
  • After enrollment, participants will be asked to complete Survey 1 either in person or by giving sending them the web link with RedCap

Randomization

  • Enrolled patients will be randomized in a 1:1 ratio using permuted blocks of 6
  • Randomization sequence will be developed through sealed envelope.com
  • Randomization and allocation will be done through RedCap

Study Procedures

  1. Enrollment
  2. Postoperative Day 0-1: Survey 1 through RedCap (takes \~10 minutes)
  3. Randomization education versus usual care

    1. Control = Standard discharge instructions, which list medications prescribed at discharge
    2. Intervention = a single page handout (see attachment) with information about how to use medications for pain after discharge. This handout contains the following instructions

      • Get baseline pain control with ibuprofen
      • Use your opioid prescription only if your pain is very bad
      • Taper your medications
      • Get rid of leftover opioid tablets
  4. At discharge all patients will receive the follow medications using PillsyCaps. These are standard medications given at discharge at our institution

    • Ibuprofen 600mg: 30 tablets
    • Hydrocodone 5mg -acetaminophen 325mg: 30 tablets
  5. Postoperative day 14: All participants will be contacted to complete Survey 2 (Takes \~ 15 minutes

    • Attempts to contact each participant will be done 3 times before they are designated as "lost to follow up"
    • If a participant is still using opioids on postoperative day 14, they should be contacted weekly until they are no longer taking opioids

Primary Outcome Median number of tablets of hydrocodone-acetaminophen used after hospital discharge

Secondary Outcomes:

  • Visual Analog Scale pain score (median)
  • Percentage of patients reporting pain since discharge as worse than expected
  • Percentage of patients obtaining additional prescriptions for pain
  • Percentage of patients with unscheduled visits for pain
  • Mean ibuprofen milligrams used hours 24-47 after cesarean
  • Mean acetaminophen milligrams used hours 24-47 after cesarean
  • Total Morphine Milligram Equivalents (MME) used per hour of inpatient stay

Risks

o Breach of confidentiality of protected health information

Reporting Adverse Events Any adverse events or unanticipated problems involving risk to participants or others will be reported to the Institutional Review Board and the Vanderbilt University Medical Center (VUMC) privacy office within 7 days of discovery.

Study Withdrawal/discontinuation Participants may withdraw at any time by providing written intent to the Primary Investigator. Participants may be removed from the study if they develop a major surgical complication after their cesarean.

Statistical Considerations

Using prior data, the average opioid MME used per person was 130 MME (SD 90) in the "average use" group. With an alpha of 5% and a beta of 80%, we estimate that 160 total participants are required to show a 30% reduction in opioid used. Assuming a lost to follow up rate of 20%, we plan to enroll 200 women.

Follow-up and Record Retention On average 100 cesareans are performed per month. With a 50% enrollment rate, we anticipate this study will take 4 months to complete

The patient list will be destroyed upon data analysis and publication. Redcap will be archived upon publication.

02

Conditions studied

  • Opioid Use
03

In context

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 833 studies on the registry; 159 are open to participants now.

Of its 124 completed or terminated interventional studies of FDA-regulated products, 92 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women 18-45 years old
  • Women undergoing cesarean delivery at VUMC

Exclusion criteria

Exclusion Criteria:

  • Major post-surgical complications:
  • cesarean hysterectomy, bowel or bladder injury, reoperation, ICU admission, wound infection or separation
  • Chronic opioid use: Taking buprenorphine during pregnancy, taking an opioid for > 7 days during pregnancy.
  • Women who do not speak English
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (actual)

Study arms

  • Experimental
    Education

    Opioid Education

    Other: Opioid Education Handout

  • No intervention
    Control

    standard discharge instructions, which lists medications prescribed at discharge

Interventions

  • OtherOpioid Education Handout

    a single page handout with information about how to use medications for pain after discharge.

06

What researchers measure

Primary outcomes

  1. Opioid Use

    Median number of tablets of hydrocodone-acetaminophen used after hospital discharge

    Time frame: 6 weeks postpartum

Secondary outcomes

  1. Disposed of Opioids Correctly

    Frequency of women reporting that they either returned their unused opioids to a pharmacy or flushed them down the toilet

    Time frame: 6 weeks postpartum

  2. Analgesic Quiz Score

    Median score on an assessment of characteristics of analgesics including side effects, risks, and benefits. Score 1-10 for each question. Higher score is better.

    Time frame: 6 weeks postpartum

  3. Additional Prescriptions

    Percentage of patients obtaining additional prescriptions for pain

    Time frame: 6 weeks postpartum

07

Results

Posted Feb 5, 2020

Participant flow

Participant flow — Overall Study
MilestoneEducationControl
Started9799
Completed8491
Not completed138
Withdrew: Prescribed non- protocol medications106
Withdrew: Lost to follow-up32

Outcome measures

PrimaryOpioid Use

Median number of tablets of hydrocodone-acetaminophen used after hospital discharge

Time frame:
6 weeks postpartum
Reported as:
Median · hydrocodone tablets
Opioid Use
hydrocodone tabletsEducationControl
Opioid Use7.5 (2 to 15)10 (2 to 16)
SecondaryDisposed of Opioids Correctly

Frequency of women reporting that they either returned their unused opioids to a pharmacy or flushed them down the toilet

Time frame:
6 weeks postpartum
Reported as:
Number · participants
Disposed of Opioids Correctly
participantsEducationControl
Disposed of Opioids Correctly3014
SecondaryAnalgesic Quiz Score

Median score on an assessment of characteristics of analgesics including side effects, risks, and benefits. Score 1-10 for each question. Higher score is better.

Time frame:
6 weeks postpartum
Reported as:
Median · score on a scale
Analgesic Quiz Score
score on a scaleEducationControl
Analgesic Quiz Score10 (9 to 10)8 (7 to 9)
SecondaryAdditional Prescriptions

Percentage of patients obtaining additional prescriptions for pain

Time frame:
6 weeks postpartum
Reported as:
Count of participants · Participants
Additional Prescriptions
ParticipantsEducationControl
Additional Prescriptions41

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Education0/97 (0%)0/97 (0%)0/97 (0%)
Control0/99 (0%)0/99 (0%)0/99 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)EducationControlTotal
Mean29.9 ± 5.430.5 ± 4.930.2 ± 5.2
Sex: Female, Male
Sex: Female, Male(Participants)EducationControlTotal
Female8491175
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EducationControlTotal
Caucasian5260112
African-American201535
Other121628
Region of Enrollment
Region of Enrollment(participants)EducationControlTotal
United States8491175
High school education or less
High school education or less(Participants)EducationControlTotal
Count of participants142337
08

Study locations

1 site
  • Sarah Osmundson
    Nashville, Tennessee 37215, United States
09

References and documents

Publications

  • Schirle LM, Dietrich MS, Lam L, Stone AL, Bruehl S, Osmundson SS. Accuracy of patient-reported versus real-time electronic postoperative opioid use outcomes. Am J Obstet Gynecol MFM. 2021 Jul;3(4):100347. doi: 10.1016/j.ajogmf.2021.100347. Epub 2021 Mar 11. No abstract available. PubMed 33716134 ↗
  • Lam L, Richardson MG, Zhao Z, Thampy M, Ha L, Osmundson SS. Enhanced discharge counseling to reduce outpatient opioid use after cesarean delivery: a randomized clinical trial. Am J Obstet Gynecol MFM. 2021 Jan;3(1):100286. doi: 10.1016/j.ajogmf.2020.100286. Epub 2020 Dec 3. PubMed 33451618 ↗

Study documents

  • Protocol and statistical analysis plan · Jul 2, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03678870
Responsible party
Sarah Osmundson (Assistant Professor, Ob/Gyn, Vanderbilt University Medical Center) — Principal investigator
First posted
Sep 20, 2018
Start date
Sep 1, 2018
Primary completion
Feb 1, 2019
Completion
Nov 1, 2019
Results posted
Feb 5, 2020
Last update
Feb 17, 2020

Study contacts

Sarah Osmundson, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion